Characteristic behavioral anomalies in rats prenatally exposed to 5-bromo-2′-deoxyuridine

International Journal of Developmental Neuroscience

Volumn 27, Issue 1, 2009, Pages 81-86

  Orito, Kensuke ^a   Morishima, Akihiko ^a   Ogawa, Tetsuo ^b   Muneoka, Katsumasa ^b   Kuwagata, Makiko ^c   Takata, Jiro ^d   Mishima, Kenichi ^d   Fujiwara, Michihiro ^d  

^a AZABU UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HATANO RESEARCH INSTITUTE   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

5 Bromo 2 deoxyuridine; Desipramine; Developmental neurotoxicity; Neurodevelopmental disorder; Paroxetine

Indexed keywords

BROXURIDINE; CARBOXYMETHYLCELLULOSE; DESIPRAMINE; METHYLPHENIDATE; PAROXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRENATAL PERIOD; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMETABOLITES; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; BROMODEOXYURIDINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; FEMALE; MALE; MAZE LEARNING; MENTAL DISORDERS; MOTOR ACTIVITY; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

RATTUS;

EID: 58249087569     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2008.09.002     Document Type: Article

References (29)

1. Arnsten A.F., Steere J.C., and Hunt R.D. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 53 (1996) 448-455
2. Barkovich A.J., Guerrini R., Battaglia G., Kalifa G., N'Guyen T., Parmeggiani A., Santucci M., Giovanardi-Rossi P., Granata T., and D'Incerti L. Band heterotopia: correlation of outcome with magnetic resonance imaging parameters. Ann. Neurol. 36 (1994) 609-617
3. Bhatnagar S., Sun L.M., Raber J., Maren S., Julius D., and Dallman M.F. Changes in anxiety-related behaviors and hypothalamic-pituitary-adrenal activity in mice lacking the 5-HT-3A receptor. Physiol. Behav. 81 (2004) 545-555
4. Biggers W.J., Barnea E.R., and Sanyal M.K. Anomalous neural differentiation induced by 5-bromo-2′-deoxyuridine during organogenesis in the rat. Teratology 35 (1987) 63-75
5. Brus R., Nowak P., Szkilnik R., Mikolajun U., and Kostrzewa R.M. Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotox. Res. 6 (2004) 317-325
6. Cerbone A., and Sadile A.G. Behavioral habituation to spatial novelty: interference and noninterference studies. Neurosci. Biobehav. Rev. 18 (1994) 497-518
7. Dobyns W.B., and Truwit C.L. Lissencephaly and other malformations of cortical development: 1995 update. Neuropediatrics 26 (1995) 132-147
8. Ferrie C.D., Jackson G.D., Giannakodimos S., and Panayiotopoulos C.P. Posterior agyria-pachygyria with polymicrogyria: evidence for an inherited neuronal migration disorder. Neurology 45 (1995) 150-153
9. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., and Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science, New York, NY 283 (1999) 397-401
10. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., Molina P.E., and Dewey S.L. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J. Pharmacol. Exp. Ther. 295 (2000) 51-57
11. Gessa G.L., Pani L., Fadda P., and Fratta W. Sleep deprivation in the rat: an animal model of mania. Eur. Neuropsychopharmacol. 5 Suppl. (1995) 89-93
12. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., Santarelli L., Beck S., and Hen R. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416 (2002) 396-400
13. Himelstein J., Newcorn J.H., and Halperin J.M. The neurobiology of attention-deficit hyperactivity disorder. Front. Biosci. 5 (2000) D461-478
14. Kolb B., Pedersen B., Ballermann M., Gibb R., and Whishaw I.Q. Embryonic and postnatal injections of bromodeoxyuridine produce age-dependent morphological and behavioral abnormalities. J. Neurosci. 19 (1999) 2337-2346
15. Kuwagata M., Muneoka K.T., Ogawa T., Takigawa M., and Nagao T. Locomotor hyperactivity following prenatal exposure to 5-bromo-2′-deoxyuridine: neurochemical and behavioral evidence of dopaminergic and serotonergic alterations. Toxicol. Lett. 152 (2004) 63-71
16. Kuwagata M., and Nagao T. Behavior and reproductive function of rat male offspring treated prenatally with 5-bromo-2′-deoxyuridine. Reprod. Toxicol. 12 (1998) 541-549
17. Kuwagata M., Ogawa T., Nagata T., and Shioda S. The evaluation of early embryonic neurogenesis after exposure to the genotoxic agent 5-bromo-2′-deoxyuridine in mice. Neurotoxicology 28 (2007) 780-789
18. Ma C.L., Arnsten A.F., and Li B.M. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biol. Psychiatry 57 (2005) 192-195
19. Mateo Y., Pineda J., and Meana J.J. Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem. 71 (1998) 790-798
20. Mechan A.O., Moran P.M., Elliott M., Young A.J., Joseph M.H., and Green R. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology (Berl) 159 (2002) 167-175
21. Muneoka K., Kuwagata M., Iwata M., Shirayama Y., Ogawa T., and Takigawa M. Dopamine transporter density and behavioral response to methylphenidate in a hyperlocomotor rat model. Congenit. Anom. 46 (2006) 155-159
22. Ogawa T., Kuwagata M., Muneoka K.T., and Shioda S. Neuropathological examination of fetal rat brain in the 5-bromo-2′-deoxyuridine-induced neurodevelopmental disorder model. Congenit. Anom. 45 (2005) 14-20
23. Orito K., Gotanda N., Murakami M., Ikeda T., Egashira N., Mishima K., and Fujiwara M. Prenatal exposure to 3,3',4,4',5-pentachlorobiphenyl (PCB126) promotes anxiogenic behavior in rats. Tohoku J. Exp. Med. 212 (2007) 151-157
24. Pilz D., Stoodley N., and Golden J.A. Neuronal migration, cerebral cortical development, and cerebral cortical anomalies. J. Neuropathol. Exp. Neurol. 61 (2002) 1-11
25. Pinard J.M., Motte J., Chiron C., Brian R., Andermann E., and Dulac O. Subcortical laminar heterotopia and lissencephaly in two families: a single X linked dominant gene. J. Neurol. Neurosurg. Psychiatry 57 (1994) 914-920
26. Ramaiya A., Johnson J.H., and Karnes H.T. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis. J. Pharm. Sci. 86 (1997) 1497-1500
27. Sobrian S.K., Marr L., and Ressman K. Prenatal cocaine and/or nicotine exposure produces depression and anxiety in aging rats. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 501-518
28. Sullivan R.M., and Brake W.G. What the rodent prefrontal cortex can teach us about attention-deficit/hyperactivity disorder: the critical role of early developmental events on prefrontal function. Behav. Brain Res. 146 (2003) 43-55
29. Webster W., Shimada M., and Langman J. Effect of fluorodeoxyuridine, colcemid, and bromodeoxyuridine on developing neocortex of the mouse. Am. J. Anat. 137 (1973) 67-85